海普瑞(09989)自欧洲药品管理局取得药品GMP证书

智通财经2025-02-14

智通财经APP讯，海普瑞(09989)发布公告，公司已于近日收到波兰卫生监督机构(Chief Pharmaceutical Inspector)根据欧洲药品管理局(EMA)相关规定发出的“Certificate of GMP Compliance of a Manufacturer”(药品GMP证书)。药品GMP证书的详情：生产地址：中国深圳市坪山区坑梓街道荣田南1号;证书编号：ISF. ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2511165463?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-14 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511165463","market":"us","top_or_hot":-1,"title":"海普瑞(09989)自欧洲药品管理局取得药品GMP证书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，海普瑞(09989)发布公告，公司已于近日收到波兰卫生监督机构(Chief Pharmaceutical Inspector)根据欧洲药品管理局(EMA)相关规定发出的“Certificate of GMP Compliance of a Manufacturer”(药品GMP证书)。药品GMP证书的详情：生产地址：中国深圳市坪山区坑梓街道荣田南1号;证书编号：ISF. ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1249977.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海普瑞(09989)自欧洲药品管理局取得药品GMP证书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海普瑞(09989)自欧洲药品管理局取得药品GMP证书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-14 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1249977.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，海普瑞(09989)发布公告，公司已于近日收到波兰卫生监督机构(Chief Pharmaceutical Inspector)根据欧洲药品管理局(EMA)相关规定发出的“Certificate of GMP Compliance of a Manufacturer”(药品GMP证书)。药品GMP证书的详情：生产地址：中国深圳市坪山区坑梓街道荣田南1号;证书编号：ISF. ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1249977.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09989","symbol_name":"海普瑞","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1249977.html","article_id":"2511165463","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511165463","pubTimestamp":1739523602,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，海普瑞 发布公告，公司已于近日收到波兰卫生监督机构根据欧洲药品管理局相关规定发出的“Certificate of GMP Compliance of a Manufacturer”。公告称，海普瑞坪山园区的新建预灌封制剂生产线项目于2022年正式启动。截至2024年，该项目已完成并首次通过欧洲联盟(欧盟)GMP认证。根据欧盟成员国之间的GMP互认制度，本次通过GMP认证表明本次接受认证的生产线已符合欧盟GMP标准。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09989":"海普瑞","BK1191":"制药","BK0188":"融资融券","BK0070":"员工持股","002399":"海普瑞","BK0239":"医药制造"},"translate_title":"Hepalink (09989) obtained the drug GMP certificate from the European Medicines Agency","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1,"002399":1},"content_text":"智通财经APP讯，海普瑞(09989)发布公告，公司已于近日收到波兰卫生监督机构(Chief Pharmaceutical Inspector)根据欧洲药品管理局(EMA)相关规定发出的“Certificate of GMP Compliance of a Manufacturer”(药品GMP证书)。药品GMP证书的详情：生产地址：中国深圳市坪山区坑梓街道荣田南1号;证书编号：ISF. 405.8.2025 MP.1 WTC/0598_01_01/13;认证产线：PFS1-PFS3灌装生产线、PFSP1-PFSP4包装线;认证产品：依诺肝素钠预灌注射液(如有) 。公告称，海普瑞坪山园区的新建预灌封制剂生产线项目于2022年正式启动。第一期工程涉及三条预灌封制剂生产线的建设，设计年产能为3.3亿支。该等生产线按照中国、欧洲及美国的药物监管标准设计建造，并将用于生产依诺肝素钠预灌注射液。截至2024年，该项目已完成并首次通过欧洲联盟(欧盟)GMP认证。根据欧盟成员国之间的GMP互认制度，本次通过GMP认证表明本次接受认证的生产线已符合欧盟GMP标准。欧洲乃公司全球制剂业务的重要市场。近年来，集团旗下依诺肝素钠制剂的市场占有率一直位居欧洲前二位。新制剂生产线获得药品GMP证书将为集团进一步推进国际化战略提供充足的产能保障，并有效提升集团的市场竞争力。此外，集团凭借其强大的预灌制剂生产能力，以及成熟的自营销售网络及渠道，集团将可强力支持并推动协助中国制药企业进军欧美市场的战略。公司相信，此举将对公司未来的业务拓展产生深远且积极的影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2511165463","isCrawlerRequest":true}